Ignite Creation Date:
2025-12-24 @ 12:18 PM
Ignite Modification Date:
2025-12-27 @ 9:40 PM
Study NCT ID:
NCT06384261
Status:
RECRUITING
Last Update Posted:
2025-09-10
First Post:
2024-04-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
Sponsor:
OncoVerity, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-07-22
Start Date Type:
ACTUAL
Primary Completion Date:
2027-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-06
Completion Date Type:
ESTIMATED
First Submit Date:
2024-04-18
First Submit QC Date:
None
Study First Post Date:
2024-04-25
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-03
Last Update Post Date:
2025-09-10
Last Update Post Date Type:
ESTIMATED